With an ability to increase CD8+ T cell activation and PD-L1 expression in the TME [250], V937 synergizes powerfully with checkpoint inhibitors, enabling T cell migration and infiltration into tumor loci [250,362,374]. The gene discussed is CD8A; the disease is neoplasm.